Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure

Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure

Abstract Aims Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin–angiotensin–aldosterone system (RAAS) inhibitors at the recommended dose or at all, frequently due to actual or feared hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is an orally adminis...

Full description

Bibliographic Details
Main Authors: Jean‐Claude Tardif, Jean Rouleau, Glenn M. Chertow, Ayman Al‐Shurbaji, Vera Lisovskaja, Stephanie Gustavson, Yanli Zhao, Nadia Bouabdallaoui, Akshay S. Desai, Alexander Chernyavskiy, Maria Evsina, Béla Merkely, John J.V. McMurray, Marc A. Pfeffer
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:ESC Heart Failure
Subjects:
Heart failure with reduced ejection fraction
RAAS inhibitors
Guideline‐directed medical therapy
Hyperkalaemia
Sodium zirconium cyclosilicate
Online Access:https://doi.org/10.1002/ehf2.14268

Internet

https://doi.org/10.1002/ehf2.14268

Similar Items